Yes it is awesome news. My understanding of the extension study is that a patient treated prior can be treated with the escalated dose when the next treated patient has successfully been treated (no adverse effects). Since the first patient cannot be treated until after the second has, we're potentially in our third patient.
The interim analysis is due in June, which will likely be tied closely with the pending ASX listing, one would think. It's certainly exciting times.
